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Abstract: Ames dwarf (df/df) mice lack growth hormone (GH), thyroid stimulating hormone and prolactin. Treatment of
juvenile df/df mice with GH alone stimulates somatic growth, reduces insulin sensitivity and shortens lifespan. Early‐life
treatment with thyroxine (T4) alone produces modest growth stimulation but does not affect longevity. In this study, we
examined the effects of treatment of juvenile Ames dwarf mice with a combination of GH + T4 and compared them to the
effects of GH alone. Treatment of female and male dwarfs with GH + T4 between the ages of 2 and 8 weeks rescued
somatic growth yet did not reduce lifespan to match normal controls, thus contrasting with the previously reported effects
of GH alone. While the male dwarf GH + T4 treatment group had no significant effect on lifespan, the female dwarfs
undergoing treatment showed a decrease in maximal longevity. Expression of genes related to GH and insulin signaling in
the skeletal muscle and white adipose tissue (WAT) of female dwarfs was differentially affected by treatment with GH + T4
vs. GH alone. Differences in the effects of GH + T4 vs. GH alone on insulin target tissues may contribute to the differential
effects of these treatments on longevity.
INTRODUCTION

conclusion which is supported by glucose tolerance and
insulin tolerance tests, as well as by a recent study
involving hyperinsulinemic-euglycemic clamps [4-7].
Importantly, Ames dwarf mice show a delayed aging
process, demonstrated by enhancements in lifespan and
healthspan including maintenance of higher insulin
sensitivity and glucose tolerance throughout life,
preservation of cognitive and neuromuscular function,
and decreased occurrence of cancer [6, 8-12].
Mechanisms of the 40-60% increase in lifespan of df/df
mice most likely include the interruption in
somatotropic (GH/IGF-1) signaling and enhanced

Ames dwarf mice (df/df) have underdeveloped anterior
pituitary glands due to a homozygous recessive deletion
at the Prop1 locus. This loss of function mutation leads
to primary hormonal deficiencies in growth hormone
(GH), thyroid stimulating hormone (TSH), and prolactin
(PRL) [1-3]. As a result, Ames dwarf mice have
secondary deficiencies in insulin-like growth factor 1(IGF-1) and thyroid hormones (T4). Furthermore, df/df
mice have reduced circulating levels of insulin and
glucose. This implies enhanced insulin sensitivity, a
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insulin sensitivity [5, 13, 14], along with enhancement
of anti-oxidant defenses and stress resistance [15-20].
Numerous studies in several animal models reinforce
the correlations between insulin sensitivity and the
effects of GH on longevity. The dietary intervention of
calorie restriction (CR) is a reduction in total calories
consumed; it produces an increase in insulin sensitivity,
lifespan, and healthspan in many animal species,
including mice [4, 21-23].While both df/df mice and CR
mice show positive signs of healthier aging, they appear
to do so via different mechanisms, considering that
df/df mice undergoing 30% CR exhibit a further
extension of longevity [1, 4, 21, 24, 25]. Furthermore,
Ames, Snell, and Laron dwarf mice all feature
disruptions in the GH/IGF-1 axis and have reduced
plasma concentrations of glucose and insulin, as well as
increases in lifespan and healthspan when compared to
normal littermates [8, 26].

the body weight of their normal siblings. The treatment
with GH plus T4 also led to increased plasma insulin,
decreased adiponectin, and decreased expression of
insulin signaling components in the liver [43].
In the present study, we have examined the impact of
six weeks of treatment of juvenile Ames dwarf mice
with a combination of GH and T4 on their longevity.
We also analyzed the effects of treating female Ames
dwarf mice with GH alone or with GH plus T4 on the
expression of genes involved in insulin signaling in
skeletal muscle (SM) and white adipose tissue (WAT).
To determine the effects of the hormonal intervention
we performed an analysis of the expression of genes
involved in the insulin signaling pathway, including
insulin receptor (IR), insulin receptor substrate-1 (IRS1), and phosphatidylinositol bisphosphate 3-kinase
(PI3K). Next, we investigated an important fulcrum in
insulin signaling pathway, the serine/threonine kinase
Akt2, as well as genes of its downstream effectors,
namely GLUT4 and forkhead box O3 (FOXO3). The
mRNA levels of the transcription factor peroxisome
proliferator-activated
receptor
gamma (PPAR-γ),
peroxisome proliferator-activated receptor gamma
coactivator 1 alpha (PGC-1α), and Adiponectin (an
adipokine) were examined, as they are important
modulators of insulin sensitivity, glucose utilization,
and lipid metabolism. Additionally, to determine the
activation of GH signals in df/df mice after the
treatment, we examined the expression of the growth
hormone receptor (GHR) gene and genes related to its
downstream effects, including insulin-like growth
factor-1 (IGF-1), STAT-1, STAT-5a, and STAT-5b.

Insulin sensitivity is also related to aging and longevity
in humans. Thus, glucose tolerance tends to decline
with age and approximately 27% of the elderly over 65
are being diagnosed with type 2 diabetes [27, 28]. In
contrast, populations of centenarians have been shown
to have improved insulin action, increased adiponectin,
and either a reduction in serum IGF-1 levels or a higher
prevalence of functional IGF-1 receptor mutations [2934]. There is a marked progressive decline in GH levels
that begin after puberty [35, 36]. However, centenarians
have not been shown to have significantly different
levels of serum GH compared to normal, healthy aged
individuals [37]. On the other hand, overexpression of
GH is associated with detrimental effects on health in
both humans and mice, including tumor development,
insulin resistance, reduced antioxidant activity, reduced
immune function, and shorter lifespan [38-41].

RESULTS
Longevity

Treatment of juvenile male Ames dwarf mice with GH
markedly increases somatic growth, but severely
attenuates insulin sensitivity, glucose tolerance, cellular
stress resistance, and longevity [5, 6, 42]. After GH
treatment is discontinued, somatic growth slows down
and body weight stabilizes at a level intermediate
between normal (wild-type) and untreated Ames dwarf
mice, while insulin sensitivity reduced by GH therapy is
eventually restored [5]. The ability of early-life, six
week GH treatment to reduce the longevity of Ames
dwarf mice applies to both females and males and is
reproducible (Hill, Arum and Bartke, unpublished
observations). Juvenile male and female Ames dwarf
mice treated for six weeks with thyroxine (T4)
experienced increases in bodyweight, yet longevity was
not significantly affected [6]. Young male Ames dwarf
mice treated with a combination of GH and T4
exhibited a major increase in bodyweight, approaching
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Consistent with our previous reports [4, 6, 18], Ames
dwarf mice lived significantly longer than normal
animals (p < 0.0001; log-rank test). Average longevity
of female and male Ames dwarf mice that had been
treated with GH + T4 between 2 and 8 weeks of age did
not differ from the longevity of dwarf mice of the same
sex that had been injected with saline. We used the
Wang/Allison method to compare the proportion of live
mice in each group at the age at which only 10% of the
population remained alive [44]. Maximal longevity of
female (p = 0.0128 by Fisher's exact test), but not male
Ames dwarf mice, was reduced by GH + T4 treatment.
Unexpectedly, treatment of normal juvenile male (but
not female) mice with GH + T4 for 6 weeks produced a
small but statistically (p = 0.0360; log-rank test)
significant increase in overall longevity (Figure 1).
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Figure 1. Longevity study. Male and Female Kaplan‐Meier survival plots of Normal (N) and Ames dwarf
(df/df) mice with either no treatment (saline) or treated with a combination of growth hormone and
thyroxine (GH + T4) (n = 24 animals per group).

Body weight and Glucose Level

Female df/df-GH mice showed a numerical increase of
fasting blood glucose levels reaching values higher
than the levels measured in the normal mice (p <
0.05). However, dwarf mice treated with GH and T4
showed no such increase with fasting blood glucose
levels resembling those in untreated df/df mice (Figure
3).

At the age of 2 months, body weight of the Ames dwarf
mice was significantly lower than phenotypically
normal (N) control mice as expected (p < 0.0001).
However, after six weeks of treatment with GH or GH
and T4, the df/df mice were significantly larger than
saline treated mutants (p < 0.0001) and matched the
body weight of normal mice (Figure 2).

Figure 3. Blood glucose comparison of 8 week old female

Figure 2. Body weight comparison of 8 week old female

Normal mice (N, n=10), Ames dwarf mice (df/df, n=10), Ames
dwarf mice treated with GH (df/df GH, n=10), and Ames dwarf
mice treated with both GH and T4 (df/df GH + T4, n=8). Groups
that do not share a superscript are different with statistical
significance (p < 0.05).

Normal mice (N, n=10), Ames dwarf mice (df/df, n=10), Ames
dwarf mice treated with GH (df/df GH, n=10), and Ames dwarf
mice treated with both GH and T4 (df/df GH + T4, n=8). Groups
that do not share a superscript are different with statistical
significance (p < 0.05).
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Gene Expression: Skeletal Muscle

Ames dwarfism or treatment with GH alone. However,
combined treatment with GH + T4 significantly reduced
PI3K mRNA expression in comparison to both N mice
and mice treated with GH alone (p < 0.01) (Figure 4).
The expression level of skeletal muscle Akt2 was
decreased in df/df mice when compared to N mice (p <
0.05). GH treatment normalized the expression of Akt2,
while GH-T4 treatment did not with no significant
difference from values measured in untreated df/df mice
(p < 0.05) (Figure 4).

There were no differences in insulin receptor (IR) gene
expression in the skeletal muscle tissue between N,
df/df and df/df-GH mice, while df/df-GH + T4 mice had
reduced IR mRNA expression (p < 0.01). IRS-1 gene
expression was significantly increased in df/df-GH mice
when compared with df/df animals (p < 0.01), yet in the
group given GH plus T4, this effect of GH was
attenuated. PI3K gene expression was not altered by

Figure 4. (A) Insulin Receptor (IR), (B) Insulin Receptor Substrate‐1 (IRS‐1), (C)
Phosphoinositide 3‐Kinase (PI3K), and (D) Akt2 relative gene expression in female Ames dwarf
(df/df) mouse skeletal muscle tissue after growth hormone (GH) and thyroxine (T4) treatment.
For A‐D, Normal (N) n = 10; df/df n = 10; df/df GH n = 10; and df/df GH + T4 n = 8. Groups that
do not share a superscript show differences with statistical significance (p < 0.05).
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Figure 5. (A) Peroxisome Proliferator‐Activated Receptor (PPAR) γ, (B) PPAR Coactivator 1α (PGC‐1α),
(C) Growth Hormone Receptor, (D) Insulin‐like Growth Factor‐1 (IGF‐1), and (E) GLUT4 relative gene
expression in female Ames dwarf (df/df) mouse skeletal muscle tissue after growth hormone (GH) and
thyroxine (T4) treatment. For A‐E, Normal (N) n = 10; df/df n = 10; df/df GH n = 10; and df/df GH + T4 n =
8. Groups that do not share a superscript show differences with statistical significance (p < 0.05).

The level of PPAR-γ mRNA in skeletal muscle was not
altered in df/df mice and not affected by GH therapy.
However, combined GH-T4 treatment significantly
reduced the PPAR-γ mRNA expression (p < 0.05)
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(Figure 5). The expression level of PGC-1α was
decreased in all groups of Ames dwarf mice, regardless
of the treatment (p < 0.05). The growth hormone
receptor (GHR) mRNA level was not altered in GH-
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deficient df/df mice and was not affected by GH.
Interestingly, df/df-GH + T4 mice showed a decrease in
the expression level of GHR when compared with either
N (p< 0.005), df/df (p < 0.05), or df/df-GH animals (p <
0.05) (Figure 5). The IGF-1 mRNA level in the skeletal
muscle was significantly increased in df/df mice when
compared to N animals (p < 0.005), and GH treatment
caused a further increase of local IGF-1 expression
(when compared with either N or df/df mice; p < 0.0005
and p < 0.005, respectively). Interestingly, addition of
T4 attenuated the effect of GH treatment and maintain-

ed the expression of IGF-1 mRNA in df/df-GH + T4 at
the level observed in df/df control mice (Figure 5). In
comparison to N animals, control Ames dwarf mice had
markedly reduced GLUT4 gene expression in (p <
0.005), and treating them with GH alone increased
GLUT4 gene expression to the levels found in normal
mice (p < 0.01). In contrast, treatment with GH plus T4
suppressed GLUT4 gene expression to levels below
those measured in the df/df and df/df-GH groups (p <
0.05, p < 0.001 respectively) (Figure 5).

Figure 6. (A) Signal Transducer and Activator of Transcription (STAT) ‐1, (B) STAT‐5a, (C) STAT‐5b, (D) Adiponectin,
and (E) FOXO3 relative gene expression in female Ames dwarf (df/df) mouse skeletal muscle tissue after growth
hormone (GH) and thyroxine (T4) treatment. For A‐E, Normal (N) n = 10; df/df n = 10; df/df GH n = 10; and df/df GH +
T4 n = 8. Groups that do not share a superscript show differences with statistical significance (p < 0.05).
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Figure 7. (A) Insulin Receptor (IR), (B) Insulin Receptor Substrate‐1 (IRS‐1), (C) Phosphoinositide 3‐Kinase (PI3K),
and (D) Akt2 relative gene expression in female Ames dwarf (df/df) mouse white adipose tissue after growth
hormone (GH) and thyroxine (T4) treatment. For A‐D, Normal (N) n = 10; df/df n = 9; df/df GH n = 9; and df/df GH +
T4 n = 8. Groups that do not share a superscript show differences with statistical significance (p < 0.05).

ponectin mRNA levels in untreated df/df mice (p <
0.05), were normalized by GH treatment (p < 0.05) but
were not affected by administration of GH together with
T4 (Figure 6).

Growth hormone treatment of dwarf mice elevated
STAT-1 gene expression (p < 0.05), but combined GH
and T4 therapy did not. STAT-1 expression in animals
treated with GH + T4 mice was significantly lower than
in the group given GH alone (p < 0.005). The STAT-5a
expression was not affected by genotype or by either of
the treatments (Figure 6). However, STAT-5b
expression was reduced by GH treatment of df/df mice
(p < 0.05), and GH-T4 treatment led to a further
significant decrease in the expression of this gene (p <
0.01). The expression of FOXO3 transcription factor
was decreased in df/df-GH + T4 group in comparison to
N, df/df and df/df-GH animals (P < 0.005, p < 0.05, and
p < 0.0005, respectively). The markedly increased adi-
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Gene Expression: White Adipose Tissue
The level of IR mRNA in white adipose tissue (WAT)
did not differ between N and df/df mice. Growth
hormone treatment suppressed IR mRNA expression in
dwarf mice (p < 0.001) with further significant decrease
in animals given GH + T4 (p < 0.005). Interestingly, IR
expression in df/df-GH + T4 animals was significantly
lower than in N mice (p < 0.05). The IRS-1 mRNA
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expression level was increased in df/df mice when
compared with N animals (p < 0.005), and normalized
by treatment with GH and T4 (p < 0.005), but not with
GH alone (Figure 7). PI3K mRNA expression was
elevated in df/df mice when compared to N littermates
(p < 0.05). GH treatment normalized PI3K expression
(p < 0.05), while GH plus T4 treatment led to a further
suppression of the levels of PI3K mRNA (when com-

pared with N, df/df and df/df-GH groups, p < 0.005, p <
0.005, p < 0.05, respectively). The level of Akt2 mRNA
was up-regulated in df/df when compared to N mice (p
< 0.05), not affected by treatment with GH alone but
reduced by treatment with GH + T4 to levels
significantly below those measured in the df/df an df/dfGH groups (p < 0.005 and p < 0.01, respectively)
(Figure 7).

Figure 8. (A) Peroxisome Proliferator‐Activated Receptor (PPAR) γ, (B) PPAR Coactivator 1α (PGC‐1α),
(C) Growth Hormone Receptor, (D) Insulin‐like Growth Factor‐1 (IGF‐1), and (E) GLUT4 relative gene
expression in female Ames dwarf (df/df) mouse white adipose tissue after growth hormone (GH) and
thyroxine (T4) treatment. For A‐E, Normal (N) n = 10; df/df n = 9; df/df GH n = 9; and df/df GH + T4 n =
8. Groups that do not share a superscript show differences with statistical significance (p < 0.05).
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Figure 9. (A) Signal Transducer and Activator of Transcription (STAT) ‐1, (B) STAT‐5a, (C) STAT‐5b, (D)
Adiponectin, and (E) FOXO3 relative gene expression in female Ames dwarf (df/df) mouse white adipose tissue
after growth hormone (GH) and thyroxine (T4) treatment. For A‐D, wild‐type (N) n = 10; df/df n = 9; df/df GH n =
9; and df/df GH + T4 n = 8. For E (FOXO3), Normal (N) n = 10; df/df n = 9; df/df GH n = 9; and df/df GH + T4 n = 7.
Groups that do not share a superscript show differences with statistical significance (p < 0.05).

Both GH and GH + T4 treatment decreased PPAR-γ
gene expression level in WAT of df/df mice (compared
with df/df mice, p <0.05, p< 0.005 respectively).
Moreover, animals in the df/df-GH + T4group had
lower PPAR-γ expression than the df/df-GH group (p <
0.05) (Figure 8), PGC-1α mRNA levels were
significantly increased in the WAT of Ames dwarf mice
compared with N controls (p < 0.005). Both GH and
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GH + T4 treatment suppressed PGC-1α mRNA in df/dfGH and df/df-GH + T4 mice to the levels maintained by
N mice (p < 0.0001, p < 0.0005 respectively). The level
of GHR mRNA was not altered in untreated df/df mice
and treatment with GH increased it to a level higher
than in N animals (p < 0.01). Interestingly, the
combined GH plusT4 therapy caused a decrease inGHR
gene expression, when compared with N, df/df, and
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df/df-GH mice (p < 0.05, p < 0.05and p < 0.005,
respectively).The expression of IGF-1 in the adipose
tissue of Ames dwarf was reduced (p < 0.005). GH
treatment increased IGF-1 mRNA levels in comparison
with N and df/df littermates (p < 0.0005 and p < 0.0001,
respectively); while, combined treatment with GH and
T4 had a much smaller effect leading to normalization
of IGF-1 expression. Ames dwarf controls showed
increased expression of the GLUT4 gene vs. N mice (p
< 0.01). While GH treatment had no significant effect
on the expression of this gene, treatment with GH plus
T4 significantly decreased GLUT4 mRNA levels when
compared with df/df and df/df-GH mice (p < 0.001 and
p < 0.005, respectively), normalizing it to the level
observed in N animals (Figure 8).

explanation for a small but statistically significant
increase in longevity in normal males treated with GH +
T4 between the ages of 2 and 8 weeks or for the absence
of a similar effect in females. Interpretation of findings
in normal animals is complicated by the impact of
injected GH and T4 on the functions of the
somatotropic and the hypothalamic-pituitary-thyroid
axis, which was not examined in the present study.
In an attempt to identify mechanisms that could have
been responsible for the differential impact of the
treatment with GH + T4 vs. GH alone on longevity, we
have examined expression of a number of genes related
to GH, IGF-1 and insulin signaling in the skeletal
muscle and WAT, important target tissues for these
hormones. The animals received GH or GH + T4 using
treatment protocols identical to those employed in the
longevity studies ([6, 43] and the present study) but
were euthanized on the day following the last injection
to compare the molecular alterations involved by these
hormonal regimens.

STAT-1 and STAT-5a gene expression were increased
in df/df as compared to N mice (p < 0.01) and
normalized by the treatment with either GH or GH + T4
(both p < 0.05) (Figure 9),. The expression of STAT-5b
showed upregulation in df/df mice when compared with
N animals and decreases in response to both GH (p <
0.05) and combined GH + T4 therapy (p < 0.0005). The
level of STAT-5b mRNA in df/df-GH + T4 mice was
lower than in df/df-GH and N mice (p < 0.01 and p <
0.005, respectively). Similarly to the findings with
STAT-5b, the expression of FOXO3 was elevated in
df/df mice in comparison to N animals (p < 0.05), and
significantly decreased by treatment with GH or GH +
T4 in comparison to saline-injected df/df mice (p <
0.05, p < 0.0001). Adiponectin expression levels did not
differ between N, df/df, and df/df-GH animals.
However, df/df-GH + T4 mice had decreased WAT
levels of adiponectin mRNA when compared with N,
df/df, and df/df-GH counterparts (p< 0.01, p < 0.005, p
< 0.05, respectively) (Figure 9).

There was no difference in bodyweight between GH
and GH + T4 treated Ames dwarf mice at the time of
sacrifice and the average body weights of df/df-GH and
df/df-GH + T4 mice matched the values in the N control
group. This differs from the results obtained by Louis et
al. [43], who reported that treatment of male Ames
dwarf mice with the same doses of GH as employed in
the present study did not fully normalize their body
weight. This difference may be related to the fact that
during the pre- and peripubertal period, male mice grow
more rapidly than females and reach higher body weight
at the age of 8 weeks (approximately 25 vs. 19 g). Our
failure to detect a reduction in blood glucose levels in
dwarf as compared to normal mice represents another
difference from the results of previous studies [5, 6, 45].
The present lack of difference in blood glucose level
can be potentially explained by the very young age of
the animals. Both df/df and N mice were at the age of 8
weeks and, at this age, N mice show no signs of insulin
resistance. In our previous work, we have shown that
the major differences in insulin resistance begin to
appear when the mice are approximately 15 months old,
which is most likely due to a decrease of insulin
sensitivity during aging in N mice and better
maintenance in long-living mutants [46].

DISCUSSION
Treatment of juvenile Ames dwarf mice with a
combination of GH and T4 for a period of 6 weeks did
not affect their average longevity. Reduction of
maximal longevity was detected only in females. These
findings contrast with the ability of treatment with GH
alone during the same period of development to reduce
longevity in both female and male dwarfs from the
same breeding colony ([6]; Hill Arum & Bartke,
unpublished observations). This difference between the
effects of treating juvenile Ames dwarf mice with GH +
T4 vs. GH -only treatment was unexpected, particularly
because both treatments produced a major increase in
somatic growth. However, six weeks of treatment of
juvenile Ames dwarfs with T4 alone did not impact
longevity in our previous study [6], even though
somatic growth was modestly increased. We have no
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Dominici and colleagues have shown that the alterations
in insulin sensitivity in df/df mice can be tissue specific
[47], which is consistent with our recent euglycemicclamp study of Ames dwarf mice [7]. In the present
study IR, IRS-1, and PI3K gene expression in skeletal
muscle showed no difference between dwarf and
normal female mice. In WAT, IRS-1, PI3K, and Akt2
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expression did differ between the N and df/df control
groups and these differences were eliminated by
treatment of the dwarfs with GH.

Females have a higher baseline level of GH, as well as
larger and more prolonged GH secretory periods
compared to males. In males, GH is present at lower
basal levels but maximal GH plasma concentrations are
higher. Thus, the twice daily GH treatment regimen
used in the present study may have more closely
mimicked the natural GH secretion patterns of males,
reaching higher plasma peak concentrations for a
shorter duration [53, 56, 57]. In this study, it is apparent
that there are some sex-related differences in the effects
of this hormonal therapy, as seen by the different effects
on lifespan. Interpreting the changes in gene expression,
it must be mentioned that changes in the mRNA levels
do not always correlate to changes in translation and
protein expression. Additional, more extensive studies
would be needed to evaluate the levels and
activation/deactivation of different signaling proteins to
determine what steps of the pathway are being regulated
by these hormones in the different tissues. These
additional steps are necessary as we reported that df/df
mice have higher whole body insulin sensitivity with
corresponding enhanced glucose uptake by WAT and
SM [7]. However, the present results based on our
measurements of mRNA levels indicate that the
regulation of this signal may differ in these two major
insulin dependent organs. These differences may have
been related to the timing of tissue collection or to
compensatory adjustments in the insulin signaling
pathway in experiments involving acute stimulation by
insulin.

Combined treatment with GH + T4 suppressed IR
expression in both WAT and muscle, and decreased
IRS-1 expression to the levels measured in normal
controls. Compared to the normal controls, IGF-1
mRNA levels in Ames dwarf mice were increased in
SM and reduced in WAT, however, the observed
reduction was not as severe as previously observed in
hepatic tissue or in plasma. This different regulation of
IGF-1 in examined tissues, especially in SM, represents
GH-independent local regulation of IGF-1 in these
tissues. It was previously reported that df/df mice have
normal levels of IGF-1 protein and mRNA in the
hippocampus when compared to N animals [48]. This
and other data suggest that GH mainly regulates hepatic
IGF-1 and its secretion to the circulation. However,
other organs can produce this growth factor, but make
only minor contributions to the circulating levels of
IGF-1 [49-52]. GH-only treatment drastically increased
local IGF-1 mRNA in both tissues while including T4
in the treatment regimen negated the effects of therapy
with GH alone. Thus, female dwarf mice readily
respond to treatment with GH and T4 in terms of
somatic growth, but fail to exhibit major changes in the
expression of genes related to insulin signaling in the
skeletal muscle or in WAT in response to this treatment.
Moreover, the results indicate that concurrent use of
exogenous T4 can modify the effects of GH therapy on
expression of numerous genes.

Furthermore, it would be pertinent to analyze the
effects of hormonal treatment on these molecular
signaling pathways at different stages of life and at
different times after completion of the hormonal
therapy. These future longitudinal experiments would
allow the detection of persistent or permanent changes
that GH or GH + T4 may induce during development.
This could identify genes or pathways that could affect
our lifespan or healthspan via developmental
programming.

Reviewing the gene expression results, a common trend
between both tissues examined in the present study is
apparent. In the muscle, the mRNA levels for the genes:
IR, PI3K, Akt2, GHR, IGF-1, GLUT4, STAT-1, STAT5b, and FOXO3, were lower in animals treated with GH
+ T4 than in those treated with GH alone. In WAT, the
combined treatment decreased IR, IRS-1, PI3K, Akt2,
PPAR-γ, GHR, IGF-1, GLUT4, STAT-5b, FOXO3, and
adiponectin gene expression. In both SM and WAT, GH
treatment alone failed to alter PPAR-γ gene expression,
yet GH + T4 treatment led to PPAR-γ mRNA decreases
in both tissues. However, some major differences were
also apparent. For PGC-1α, both treatments produced
expression levels mimicking those in the N control
group in the WAT but not in the muscle. GLUT4
showed strikingly different effects of genotype and
treatment in SM as compared to WAT.

In conclusion, combining T4 treatment with GH therapy
suppressed mRNA expression for several genes
including GLUT4 and IGF-1compared to GH injections
alone. Thyroxine suppressed the expression of genes
involved in the GH signaling pathway in the muscle,
including the GHR gene, thus counteracting some of the
effects of GH replacement in the GH + T4 group. It is
tempting to speculate that these actions of exogenous
T4 may have been responsible for eliminating the
impact of concomitant GH therapy on longevity, or at
least may have contributed to the differential impact of
GH + T4 vs. GH alone on lifespan. It is also possible
that the impact of thyroid hormones on the development

Differential impact of GH + T4 treatment on longevity
of males and females was not entirely unexpected.
There are major sex differences in the pulsatile pattern
of GH secretion in both humans and rodents [53-55].
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and maturation of the central nervous system and other
organs results in shortening or a temporal shift of the
period when GH can produce effects (most likely
epigenetic) that alter the course of aging and modulate
longevity. By elucidating the effects of GH and T4
replacement therapy on the insulin signaling pathway of
GH and TSH deficient Ames dwarf mice, we hope to
enhance understanding of the interactions between these
hormones in the physiological control of whole body
insulin sensitivity, aging and longevity. Progress in this
area could support development of new, safe ways to
improve glucose homeostasis in type 2 diabetic patients
and in the elderly, promoting better health and quality
of life for the future.

Comparison of the effects of treatment with GH alone
vs. GH plus T4. At the age of 2 weeks, phenotypically
normal and Ames dwarf female mice were divided into
four experimental groups, including: (i) a control group
of normal heterozygous (N) mice injected with 0.9%
saline, (ii) Ames dwarfs (df/df) treated with 0.9%
saline, (iii) Ames dwarfs treated with porcine GH
(df/df-GH), and Ames dwarfs treated with GH and T4
(df/df-GH + T4). There were 8-10 animals in each
group. Hormone treatment started at 2 weeks of age and
continued for 6 weeks. Twenty-four hours after the last
injection and after an overnight fast, the mice were
sacrificed by isoflurane anesthesia followed by cervical
dislocation. Fasting blood glucose levels were measured
before sacrifice in blood collected from the tail vein
using the OneTouch Ultra glucose meter (Life Scan,
Inc. Milpitas, CA). Tissues were harvested, immediately
frozen on dry ice and stored at -80⁰C until analysis [42,
43].

MATERIALS AND METHODS
Animals. In a breeding colony, phenotypically normal
heterozygous (N) females were mated with homozygous
dwarf (df/df) mutant males to produce the Ames dwarf
and N mice. The mice were housed under light- and
temperature- controlled conditions, with a 12-hour light
and 12-hour dark cycle and the temperature maintained
at 20-23⁰C. Nutritionally balanced food was provided
ad libitum (Rodent Laboratory Chow 5001: 23.4%
protein, 4.5% fat, 5.8% crude fiber; LabDiet PMI Feeds,
Inc., St Louis, MO). The animal studies were completed
at Southern Illinois University in Springfield Illinois
following SIU Laboratory Animal Care Committee
approval [42, 43].

Treatment. For preparation of the GH, porcine GH
(Alpharma, Victoria, Australia) was dissolved in 0.1M
NaHCO3 for stability, then 0.9% saline was added to
make a single injection concentration of 21μg/50μL for
the average animal body weight of 7g (3μg/g of body
weight); pH was adjusted from 8.3 to 7.8. GH injections
were performed twice a day on weekdays with each
subcutaneous injection administering half the daily dose
(~3μg/g); the first injection was ~9am and the second
was ~4pm (~6μg/g/day total GH treatment). On
weekends, only one injection was performed with the
full daily dosage (~6μg/g/day).

Effects of treatment of juvenile normal and ames dwarf
mice with GH plus T4 on longevity. Exogenous T4
stimulates somatic growth of Ames dwarf mice and
enhances the growth-promoting effects of GH [6, 43].
Treatment of juvenile Ames dwarfs with GH reduces
their longevity, while treatment with T4 does not [6]. In
view of these observations, we decided to examine the
impact of early-life treatment with a combination of GH
and T4 on the longevity of normal and Ames dwarf
mice. Starting at the age of 2 weeks, female and male
normal and Ames dwarf mice were injected twice daily
with saline or with porcine GH (twice daily) plus Lthyroxine (three times per week) (See details later in
section). The treatments were continued for six weeks.
There were 24 animals per genotype/sex/treatment
group (i.e. 24 N male control mice, 24 N male GH + T4,
24 df/df male control, 24 df/df male GH + T4, 24 N
female control mice, 24 N female GH + T4, 24 df/df
female control and 24 df/df female GH + T4). The
animals were checked daily for survival. The dates of
death were recorded. In some instances, animals that
appeared moribund and unlikely to survive longer than
another 24-48 hours were euthanized and the date of
euthanasia was used for longevity determination.

www.impactaging.com

For the preparation of the T4, L-thyroxine (Sigma, St
Louis, MO) was dissolved in a 0.9% saline solution
with a pH of 7.8. It was administered three times per
week (Monday, Wednesday, and Friday) via
subcutaneous injections (0.1μg/g body weight; 0.7
μg/50μL dose) and administered in conjunction with the
respective morning GH doses, albeit delivered in
separate injections.
The doses were selected on the basis of previous studies
in Ames dwarf mice [42, 43].
Real-time PCR. Hind leg skeletal muscle and periovarian white adipose tissue (WAT) RNA were used for
the analysis of the expression levels of the following
genes: IR, IRS-1, PI3K, Akt2, PPAR-γ, PGC-1α, GHR,
IGF-1, GLUT4, STAT-1, STAT-5a, STAT-5b,
Adiponectin, and FOXO3. First, total mRNA was
extracted from the sample tissue using the Qiagen
miRNeasy Mini Kit. Approximately 75mg of skeletal
muscle tissue was cut from each sample, and then
placed in a 1.5mL safe-lock tube with 1mm Zirconium
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oxide beads and 700μL of QIAzol Lysis Reagent.
Samples were homogenized in a bullet blender at speed
10 for 2 minute periods, and then cooled on wet ice for
2 minutes. This process of blending and cooling was
repeated 3 times per sample, or until well homogenized.
From here, the Quick-start Protocol included in the kit
was followed as outlined by Qiagen, including the
DNase digest steps. The result of using the kit was
approximately 40μL of purified mRNA in nuclease free
water (NF H2O). Approximate total RNA concentration
was determined for normalization using agarose gel
electrophoresis as well as Nanodrop procedure with the
Epoch Gen5 Plate Reader (see appendix for procedure
details). RNA extraction from white adipose tissue was
performed in the same way, except 50-60mg of sample
tissue was used, 0.5mm Zinc Oxide beads were used,
and the bullet blender was set at speed 8 for 3 min.

expression of 1, and all other samples were calculated
in relation to this first sample. The results of the
normal (N) group were averaged, and all other results
were divided by this average to obtain the fold change
of expression of the genes of interest compared to this
control group [43].
Statistical analysis – longevity. Overall survival was
tested by log-rank test, using GraphPad Prism 5.
Maximal survivorship was evaluated as previously
described [44].
Statistical analysis – RT PCR. Microsoft Excel and
GraphPad Prism5 software was used to calculate the
raw data. Statistics were calculated on Prism5 via onetailed P-values for unpaired t tests. Differences between
groups that generated a p-value less than 0.05 were
considered statistically significant.

Following the RNA extraction procedure, the cDNA
synthesis was performed using the Bio-Rad iScript kit.
After combining the master-mix (5x iScript reaction
mix and iScript reverse transcriptase) with mRNA
templates (derived from the tissue samples) in PCR
tubes according to protocol, the reaction mix samples
were placed into a Bio-Rad MJ Mini Personal Thermal
Cycler. The machine conditions were set at 25⁰C for 5
min, 42⁰C for 30 min, and 85⁰C for 5 min, and then
held at 4⁰C when finished. This led to cDNA samples in
20μL of NF H2O; NF H2O was added to each sample to
dilute them and narrow the range of B2M cycle
threshold (CT) values with RT-PCR (see below). The
cDNA samples were stored at 4⁰C until analysis (if
there was a longer period of time between cDNA
synthesis and RT-PCR analysis, the cDNA samples
were frozen at -20⁰C).
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